Drug interactions
Brexucabtagene autoleucel + Capecitabine
Severity: Major
Brexucabtagene autoleucel and Capecitabine: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Capecitabine can cause lymphopenia and myelosuppression, which may impair collection, expansion and persistence of CAR T cells. It also adds to the infection risk after CAR T therapy.
What this interaction means in plain words
Brexucabtagene autoleucel and Capecitabine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Brexucabtagene autoleucel belongs to Oncology; Capecitabine belongs to Oncology.
Why it happens
Cytotoxic myelosuppression and lymphodepletion may compromise CAR T-cell function and add to immunosuppression.
What to do
Avoid capecitabine in the window before leukapheresis and during CAR T recovery unless clearly needed. Coordinate timing with the CAR T team and monitor for infection and cytopenias.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Brexucabtagene autoleucel and Capecitabine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Capecitabine
Other interactions of Brexucabtagene autoleucel
Frequently asked questions
Can I take Brexucabtagene autoleucel with Capecitabine?
MediHelp rates the interaction as major. Brexucabtagene autoleucel and Capecitabine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Capecitabine can cause lymphopenia and myelosuppression, which may impair collection, expansion and persistence of CAR T cells. It also adds to the infection risk after CAR T therapy.
How serious is the interaction between Brexucabtagene autoleucel and Capecitabine?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid capecitabine in the window before leukapheresis and during CAR T recovery unless clearly needed. Coordinate timing with the CAR T team and monitor for infection and cytopenias.
What other medicines interact with Capecitabine?
MediHelp also lists interactions of Capecitabine with, for example, Adenovirus types 4 and 7 live, Arsenic trioxide, Axicabtagene ciloleucel. The full list is on the Capecitabine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
